Abstract
Alzheimer’s disease (AD) is characterized by three major histopathological hallmarks: β-amyloid deposits, neurofibrillary tangles and gliosis. While neglected for decades, the neuroinflammatory processes coordinated by microglia are now accepted as etiologic events in AD evolution. Microglial cells are found in close vicinity to amyloid plaques and display various activation phenotypes determined by the expression of a wide range of cytokines, chemokines, and innate immune surface receptors. During the development of AD pathology, microglia fail to restrict amyloid plaques and may contribute to neurotoxicity and cognitive deficit. Nevertheless, under specific activation states, microglia can participate in cerebral amyloid clearance. This review focuses on the complex relationship between microglia and Aβ pathology, and highlights both deleterious and beneficial roles of microglial activation states in the context of AD. A deeper understanding of microglial biology will hopefully pave the way for next-generation AD therapeutic approaches aimed at harnessing these enigmatic innate immune cells of the central nervous system.
Keywords: Alzheimer disease, amyloid-β peptide, chemokine, cytokine, gliosis, inflammation, innate immunity, microglia, neuroinflammation, phagocytosis.
CNS & Neurological Disorders - Drug Targets
Title:Innate Immunity in Alzheimer’s Disease: A Complex Affair
Volume: 12 Issue: 5
Author(s): Marie-Victoire Guillot-Sestier and Terrence Town
Affiliation:
Keywords: Alzheimer disease, amyloid-β peptide, chemokine, cytokine, gliosis, inflammation, innate immunity, microglia, neuroinflammation, phagocytosis.
Abstract: Alzheimer’s disease (AD) is characterized by three major histopathological hallmarks: β-amyloid deposits, neurofibrillary tangles and gliosis. While neglected for decades, the neuroinflammatory processes coordinated by microglia are now accepted as etiologic events in AD evolution. Microglial cells are found in close vicinity to amyloid plaques and display various activation phenotypes determined by the expression of a wide range of cytokines, chemokines, and innate immune surface receptors. During the development of AD pathology, microglia fail to restrict amyloid plaques and may contribute to neurotoxicity and cognitive deficit. Nevertheless, under specific activation states, microglia can participate in cerebral amyloid clearance. This review focuses on the complex relationship between microglia and Aβ pathology, and highlights both deleterious and beneficial roles of microglial activation states in the context of AD. A deeper understanding of microglial biology will hopefully pave the way for next-generation AD therapeutic approaches aimed at harnessing these enigmatic innate immune cells of the central nervous system.
Export Options
About this article
Cite this article as:
Guillot-Sestier Marie-Victoire and Town Terrence, Innate Immunity in Alzheimer’s Disease: A Complex Affair, CNS & Neurological Disorders - Drug Targets 2013; 12 (5) . https://dx.doi.org/10.2174/1871527311312050008
DOI https://dx.doi.org/10.2174/1871527311312050008 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Herpesvirus Encoded dUTPase as a Potential Chemotherapeutic Target
Current Protein & Peptide Science Blood-Brain Barrier P-Glycoprotein Function in Neurodegenerative Disease
Current Pharmaceutical Design TNF-α Inhibition as a Treatment Strategy for Neurodegenerative Disorders: New Drug Candidates and Targets
Current Alzheimer Research Pharmacology of Nitric Oxide: Molecular Mechanisms and Therapeutic Strategies
Current Pharmaceutical Design Novel Concepts for Anti-Infective Activity of Cytokines, Chemokines and Diverse Agents
Recent Patents on Anti-Infective Drug Discovery Himalayan Plant Species as Pesticidal Agents
Mini-Reviews in Organic Chemistry Editorial [Hot Topic:Active and Passive Aβ-Immunotherapy: Preclinical and Clinical Studies and Future Directions: Part I (Guest Editors: Michael G. Agadjanyan and David H. Cribbs)]
CNS & Neurological Disorders - Drug Targets Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Immune Response to Herpes Simplex Virus and γ134.5 Deleted HSV Vectors
Current Gene Therapy Molecular and Biological Aspects of the Bovine Immunodeficiency Virus
Current HIV Research Rho as a Target to Promote Repair: Translation to Clinical Studies with Cethrin
Current Pharmaceutical Design Cellular Reservoirs of HIV-1 and their Role in Viral Persistence
Current HIV Research AD Vaccines: Conclusions and Future Directions
CNS & Neurological Disorders - Drug Targets Editorial [Hot topic: Structural Disorder in Viral Proteins (Guest Editor: Sonia Longhi)]
Protein & Peptide Letters Animal Models in Neurology: Drawbacks and Opportunities
Current Pharmaceutical Design Can Acetylcholinesterase Serve as a Target for Developing More Selective Insecticides?
Current Drug Targets Gibbs Sampling Shows Possibilities of B-Cell Epitope Signatures
Protein & Peptide Letters The Pulse of Drug Development for Alzheimers Disease
Reviews on Recent Clinical Trials An Overview on Global Trends in Nanotechnological Approaches for Alzheimer Therapy
Current Drug Metabolism Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology